medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Number 1

<< Back Next >>

Ann Hepatol 2017; 16 (1)

High Clinical Manifestation Rate in an Imported Outbreak of Hepatitis E Genotype 1 Infection in a German Group of Travellers Returning from India

Pischke S, Schulze-zur-Wiesch J, Lütgehetmann M, Kreuels B, Lueth S, Kapaun P, Benten D, Schmiedel S, Sterneck M, Lohse AW, Polywka S

Language: English
References: 17
Page: 57-62
PDF size: 153.60 Kb.


ABSTRACT

Background. There are only few reports about travel-associated, imported tropical hepatitis E virus (HEV) genotype 1 infections within Western travellers. We describe the clinical course of a single outbreak of hepatitis E in a German travellers group returning from India and compare the results of two commercial HEV-seroassays. Material and methods. After identifying hepatitis E in an index patient returning from a journey to India all 24 members of this journey were tested for anti-HEV-IgG and IgM using two commercial seroassays (Wantai and Mikrogen), for HEV-RNA by PCR and HEV-Ag by an antigen-assay (Wantai). Results. 5/24 (21%) individuals were viraemic with viral loads between 580-4,800,000 IU/mL. Bilirubin and ALT levels in these patients ranged from 1.3-14.9 mg/dL (mean 7.3 mg/dL, SD 5.6 mg/dL) and 151-4,820 U/L (mean 1,832U/L, SD 1842U/L), respectively and showed significant correlations with viral loads (r = 0.863, p ‹ 0.001; r = 0.890, p ‹ 0.001). No risk factor for food-borne HEV-transmission was identified. All viraemic patients (5/5) tested positive for anti-HEV-IgG and IgM in the Wantai-assay but only 4/5 in the Mikrogen-assay. Wantai-HEV-antigen-assay was negative in all patients. Six months later all previously viraemic patients tested positive for anti-HEV-IgG and negative for IgM in both assays. However, two non-viremic individuals who initially tested Wantai-IgM-positive stayed positive indicating false positive results. Conclusions. Despite the exact number of exposed individuals could not be determined HEV genotype 1 infections have a high manifestation rate of more than 20%.The Wantai-antigen-test failed, the Wantai-IgMrapid- test and the Mikrogen-IgM-recomblot showed a better performance but still they cannot replace real-time PCR for diagnosing ongoing HEV-infections.


REFERENCES

  1. Teshale EH, Hu DJ, Holmberg SD. The two faces of hepatitis E virus. Clin Infect Dis 2010 51: 328-34. Doi: 10.1086/ 653943.

  2. Pischke S, Wedemeyer H. Hepatitis E virus infection: multiple faces of an underestimated problem. J Hepatol 2013; 58: 1045-6. Doi: 10.1016/j.jhep.2012.12.013.

  3. Rein DB, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology 2012; 55: 988-97. Doi: 10.1002/ hep.25505.

  4. Pischke S, Behrendt P, Bock CT, Jilg W, Manns MP, Wedemeyer H. Hepatitis E in Germany—an under-reported infectious disease. Dtsch Arztebl Int 2014; 111: 577-83. Doi: 10.3238/arztebl.2014.0577.

  5. Dalton HR, Bendall RP, Rashid M, Ellis V, Ali R, Ramnarace R, Stableforth WE, et al. Host risk factors and autochthonous hepatitis E infection. Eur J Gastroenterol Hepatol 2011; 23: 1200-5. Doi: 10.1097/MEG.0b013e32834ca4da.

  6. Hewitt PE, Ijaz S, Brailsford SR, Brett R, Dicks S, Haywood B, Kennedy IT, et al. Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet 2014; 384: 1766-73. Doi: 10.1016/S0140- 6736(14)61034-5.

  7. Garson JA, Ferns RB, Grant PR, Ijaz S, Nastouli E, Szypulska R, Tedder RD. Minor groove binder modification of widely used TaqMan probe for hepatitis E virus reduces risk of false negative real-time PCR results. J Virol Methods 2012; 186: 157-60. Doi: 10.1016/j.jviromet.2012.07.027.

  8. Zhai L, Dai X, Meng J. Hepatitis E virus genotyping based on full-length genome and partial genomic regions. Virus Res 2006; 120: 57-69. Doi: 10.1016/j.virusres.2006.01.013.

  9. Smith DB, Simmonds P, Izopet J, Oliveira-Filho EF, Ulrich RG, Johne R, Koenig M, et al. Proposed reference sequences for Hepatitis E virus subtypes. J Gen Virol 2016. Doi: 10.1099/ jgv.0.000393.

  10. Allweiss L, Gass S, Giersch K, Groth A, Kah J, Volz T, Rapp G, et al. Human liver chimeric mice as a new model of chronic hepatitis E virus infection and preclinical drug evaluation. J Hepatol 2016. Doi: 10.1016/j.jhep.2016.01.011.

  11. Gupta E, Pandey P, Pandey S, Sharma MK, Sarin SK. Role of hepatitis E virus antigen in confirming active viral replication in patients with acute viral hepatitis E infection. J Clin Virol 2013; 58: 374-7. Doi: 10.1016/j.jcv.2013.07.019.

  12. Wedemeyer H, Pischke S. Hepatitis: Hepatitis E vaccination— is HEV 239 the breakthrough? Nat Rev Gastroenterol Hepatol 2011; 8: 8-10. Doi: 10.1038/nrgastro.2010.207.

  13. Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, Wang H, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double- blind placebo-controlled, phase 3 trial. Lancet 2010; 376: 895-902. Doi: 10.1016/S0140-6736(10)61030-6.

  14. Shata MT, Navaneethan U. The mystery of hepatitis E seroprevalence in developed countries: is there subclinical infection due to hepatitis E virus? Clin Infect Dis 2008; 47: 1032-4. Doi: 10.1086/591971.

  15. Said B, Ijaz S, Kafatos G, Booth L, Thomas HL, Walsh A, Ramsay M, et al. Hepatitis E outbreak on cruise ship. Emerg Infect Dis 2009; 15: 1738-44. Doi: 10.3201/eid1511.091094.

  16. Wenzel JJ, Preiss J, Schemmerer M, Huber B, Jilg W. Test performance characteristics of Anti-HEV IgG assays strongly influence hepatitis E seroprevalence estimates. J Infect Dis 2013; 207: 497-500. Doi: 10.1093/infdis/jis688.

  17. Pischke S, Polywka S, Haag F, Iking-Konert C, Sterneck M, Lütgehetmann M, Dammermann W, et al. Association of hepatitis E virus and essential cryoglobulinemia? J Clin Virol 2015; 67: 23-4. Doi: 10.1016/j.jcv.2015.03. 020.




2020     |     www.medigraphic.com